Static or locally advanced prostate Lopinavir 192725-17-0 cancer, randomized to CAB or surgical / medical castration alone.63 In the overall analysis was 5-year survival rate 25.4% vs. 23.6% with CAB with castration alone, a difference was not statistically significant. The results of these patients, the flutamide and nilutamide appeared somewhat more favorable than the total population Lkerung with 5-year survival rate of 27.6% and 24.7% for CAB to castration alone. The results of studies including normal bicalutamide were not available for this meta-analysis. Other meta-analyzes have increased Hte rate of side effects when using the RTA, particularly gastrointestinal toxicity T more and ophthalmic adverse effects specified events.64 The overall benefits and risks of the cab when tested in the R to the CAB with the patient. Bicalutamide seems better than other funds in the same immediate or class.62 sp Teren hormone therapy for M Nnern with prostate cancer symptoms usually have tolerated ADT initiated immediately. There are a number of clinical scenarios, but where there is dispute about the decision to ADT tt Open or move to a treatment time sp Ter. These areas are asymptomatic, especially the uncertainty of M Nnern with rising PSA after primary Ren treatment only once, but M Men who have metastatic asymptomatic radiologic, and pathologic node of those positive disease. As mentioned HNT, prospective data are lacking on this issue in patients with a PSA biochemical progression. Ongoing studies aim to shed light in this setting and include the Canadian Early vs. sp T androgen ablation and the Australian study schedule and neuseel Ndischen study of androgen deprivation. Until then, there are concerns about the risks and benefits of early initiation of treatment compared to a strategy of active surveillance because of a lack of evidence supporting a survival advantage and the risk of l Stigen and potentially serious side effects. Be closely monitoring these patients allows the assessment of symptoms or signs of metastatic disease in both clinical and imaging J Hrlichen bone and the determination of testosterone and PSA doubling time of Lebensqualit t. 65 are held in the absence of ADT, and ADT can be accommodated on the progression of symptomatic or radiographic metastases in open surgery. In addition, expert guidance in light of the registration of clinical trials suggest for these patients.47 The majority of the data at the time of initiation of ADT is advanced setting, where ADT is initiated soon after diagnosis of prostate cancer at the time of disease progression compared . A number of controlled studies Randomized strips VER Were published comparing early or late ADT ended at M Nnern with localized or locally advanced disease.66 The SAC 08/88 was the beginning of the trial for a Unf Ability to accumulate closed predefined number of patients. Patients were randomized to receive either an immediate or late Teren Sitagliptin Januvia orchiectomy in the symptomatic tumor progression. There was a trend toward more accurate survival rate for cancer in the immediate group, but there was no difference in OS between the two groups. Interestingly, 42% of patients in the deferred arm prostate cancer therapy.66 never needed addition to the EORTC study, 30 891, M nnern With localized prostatectomy.